Department of Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
Cardiometabolic Programme-NIHR UCLH/UCL BRC, London, UK.
J Thromb Haemost. 2018 Apr;16(4):646-651. doi: 10.1111/jth.13953. Epub 2018 Feb 2.
The interaction between platelets and the vessel wall is mediated by various receptors and adhesive proteins, of which von Willebrand factor (VWF) is the most prominent. The multimeric size of VWF is an important determinant of a more intense platelet-vessel wall interaction, and is regulated by the VWF-cleaving protease ADAMTS-13. A deficiency in ADAMTS-13 leads to higher concentrations of ultralarge VWF multimers and pathological platelet-vessel wall interactions, in its most typical and extreme form leading to thrombocytopenic thrombotic purpura, a thrombotic microangiopathy characterized by thrombocytopenia, non-immune hemolysis, and organ dysfunction. Thrombotic microangiopathy associated with low levels of ADAMTS-13 may be a component of the coagulopathy observed in patients with sepsis. Here, we review the potential role of ADAMTS-13 deficiency and ultralarge VWF multimers in sepsis, and their relationship with sepsis severity and prognosis. In addition, we discuss the possible benefit of restoring ADAMTS-13 levels or reducing the effect of ultralarge VWF as an adjunctive treatment in patients with sepsis.
血小板与血管壁的相互作用是由各种受体和黏附蛋白介导的,其中血管性血友病因子(von Willebrand factor,VWF)最为突出。VWF 的多聚体大小是血小板与血管壁相互作用增强的一个重要决定因素,由 VWF 切割蛋白酶 ADAMTS-13 调节。ADAMTS-13 缺乏会导致超大 VWF 多聚体浓度升高,导致病理性血小板与血管壁相互作用,在最典型和极端的形式下导致血小板减少性血栓性紫癜,这是一种以血小板减少、非免疫性溶血性贫血和器官功能障碍为特征的血栓性微血管病。与 ADAMTS-13 水平降低相关的血栓性微血管病可能是脓毒症患者凝血功能障碍的一个组成部分。在这里,我们回顾了 ADAMTS-13 缺乏和超大 VWF 多聚体在脓毒症中的潜在作用,以及它们与脓毒症严重程度和预后的关系。此外,我们还讨论了恢复 ADAMTS-13 水平或降低超大 VWF 作用作为脓毒症患者辅助治疗的可能益处。